← Back to Discover
EcoR1 Capital, LLC
Period ended Jun 30, 2026 · Latest filing Aug 14, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2026: $2,056,733,459
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- ZYMEWORKS INC · COM · 98985Y108 · shares: $600,445,942
- ANAPTYSBIO INC · COM · 032724106 · shares: $531,906,345
- AKTIS ONCOLOGY INC · COM · 01021M104 · shares: $155,492,636
- CG ONCOLOGY INC · COM · 156944100 · shares: $106,170,015
- ETON PHARMACEUTICALS INC · COM · 29772L108 · shares: $78,624,156
- CRISPR THERAPEUTICS AG · NAMEN AKT · H17182108 · shares: $75,771,113
- ORIC PHARMACEUTICALS INC · COM · 68622P109 · shares: $72,865,496
- FIRST TRACKS BIOTHERAPEUTICS · ORD SHS ADDED · 337185102 · shares: $63,871,322
- LAKEFRONT BIOTHERAPEUTICS NV · SPON ADR · 36315X101 · shares: $49,980,228
- NEUROGENE INC · COM · 64135M105 · shares: $39,983,706
Reported holdings
33 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| ZYMEWORKS INC | COM | 98985Y108 | — | 22,970,388 shares | $600,445,942 |
| ANAPTYSBIO INC | COM | 032724106 | — | 7,880,094 shares | $531,906,345 |
| AKTIS ONCOLOGY INC | COM | 01021M104 | — | 4,824,469 shares | $155,492,636 |
| CG ONCOLOGY INC | COM | 156944100 | — | 1,494,300 shares | $106,170,015 |
| ETON PHARMACEUTICALS INC | COM | 29772L108 | — | 2,171,938 shares | $78,624,156 |
| CRISPR THERAPEUTICS AG | NAMEN AKT | H17182108 | — | 1,389,276 shares | $75,771,113 |
| ORIC PHARMACEUTICALS INC | COM | 68622P109 | — | 6,728,116 shares | $72,865,496 |
| FIRST TRACKS BIOTHERAPEUTICS | ORD SHS ADDED | 337185102 | — | 3,174,519 shares | $63,871,322 |
| LAKEFRONT BIOTHERAPEUTICS NV | SPON ADR | 36315X101 | — | 1,667,119 shares | $49,980,228 |
| NEUROGENE INC | COM | 64135M105 | — | 1,271,342 shares | $39,983,706 |
| CG ONCOLOGY INC | COM | 156944100 | CALL | 561,500 shares | $39,894,575 |
| STOKE THERAPEUTICS INC | COM | 86150R107 | — | 735,000 shares | $24,049,200 |
| FULCRUM THERAPEUTICS INC | COM | 359616109 | — | 6,549,866 shares | $23,972,510 |
| LEGEND BIOTECH CORP | SPONSORED ADS | 52490G102 | — | 800,000 shares | $23,104,000 |
| BRIDGEBIO ONCOLOGY THERAPEUT | COM NEW | 107924102 | — | 2,823,126 shares | $21,512,220 |
| MBX BIOSCIENCES INC | COM | 55287L101 | — | 388,500 shares | $21,445,200 |
| ZENAS BIOPHARMA INC | COM | 98937L105 | — | 789,500 shares | $20,037,510 |
| ATARA BIOTHERAPEUTICS INC | COM NEW | 046513206 | — | 1,552,000 shares | $17,816,960 |
| RELAY THERAPEUTICS INC | COM | 75943R102 | — | 697,948 shares | $13,058,607 |
| AURA BIOSCIENCES INC | COM | 05153U107 | — | 1,666,667 shares | $11,833,336 |
| ODYSSEY THERAPEUTICS INC | COMMON STOCK ADDED | 67613T104 | — | 555,555 shares | $10,394,434 |
| EIKON THERAPEUTICS INC | COM | 282564103 | — | 732,606 shares | $9,560,508 |
| PHARVARIS N V | COM | N69605108 | — | 235,000 shares | $8,126,300 |
| ZURA BIO LTD | CLASS A ORD SHS | G9TY5A101 | — | 1,179,715 shares | $6,960,319 |
| PHATHOM PHARMACEUTICALS INC | COM | 71722W107 | — | 625,000 shares | $6,781,250 |
| NURIX THERAPEUTICS INC | COM | 67080M103 | — | 270,000 shares | $6,550,200 |
| ERASCA INC | COM | 29479A108 | — | 330,000 shares | $6,045,600 |
| ELOXX PHARMACEUTICALS INC | COM NEW ADDED | 29014R301 | — | 400,000 shares | $5,552,000 |
| AARDVARK THERAPEUTICS INC | COM | 002942100 | — | 396,194 shares | $2,282,077 |
| HELIX ACQUISITION CORP III USD | CL A ORD SHS | G4444S107 | — | 200,000 shares | $2,128,000 |
| MEREO BIOPHARMA GROUP PLC | SPON ADS | 589492107 | — | 1,000,000 shares | $317,700 |
| SURROZEN INC | *W EXP 08/01/203 | 86889P117 | — | 4,444 shares | $115,322 |
| AARDVARK THERAPEUTICS INC | COM | 002942100 | CALL | 14,700 shares | $84,672 |